Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza

Marc Rondy, Odile Launay, Jesus Castilla, Simona Costanzo, Joan Puig-Barberà, Giedre Gefenaite, Amparo Larrauri, Caterina Rizzo, Daniela Pitigoi, Ritva K. Syrjänen, Ausenda Machado, Sanja Kurečić Filipović, Judit Krisztina Horváth, Iwona Paradowska-Stankiewicz, Sierk Marbus, Alain Moren, InNHOVE/I-MOVE+working group

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

In Europe, annual influenza vaccination is recommended to elderly. From 2011 to 2014 and in 2015–16, we conducted a multicentre test negative case control study in hospitals of 11 European countries to measure influenza vaccine effectiveness (IVE) against laboratory confirmed hospitalised influenza among people aged ≥65 years. We pooled four seasons data to measure IVE by past exposures to influenza vaccination. We swabbed patients admitted for clinical conditions related to influenza with onset of severe acute respiratory infection ≤7 days before admission. Cases were patients RT-PCR positive for influenza virus and controls those negative for any influenza virus. We documented seasonal vaccination status for the current season and the two previous seasons. We recruited 5295 patients over the four seasons, including 465A(H1N1)pdm09, 642A(H3N2), 278 B case-patients and 3910 controls. Among patients unvaccinated in both previous two seasons, current seasonal IVE (pooled across seasons) was 30% (95%CI: −35 to 64), 8% (95%CI: −94 to 56) and 33% (95%CI: −43 to 68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively. Among patients vaccinated in both previous seasons, current seasonal IVE (pooled across seasons) was −1% (95%CI: −80 to 43), 37% (95%CI: 7–57) and 43% (95%CI: 1–68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively. Our results suggest that, regardless of patients’ recent vaccination history, current seasonal vaccine conferred some protection to vaccinated patients against hospitalisation with influenza A(H3N2) and B. Vaccination of patients already vaccinated in both the past two seasons did not seem to be effective against A(H1N1)pdm09. To better understand the effect of repeated vaccination, engaging in large cohort studies documenting exposures to vaccine and natural infection is needed.

Original languageEnglish
Pages (from-to)4298-4306
Number of pages9
JournalVaccine
Volume35
Issue number34
DOIs
Publication statusPublished - Aug 3 2017

Fingerprint

influenza
Human Influenza
Vaccination
vaccination
Influenza Vaccines
vaccines
Orthomyxoviridae
Vaccines
Respiratory Tract Infections
Case-Control Studies
case-control studies
cohort studies
Hospitalization
Cohort Studies
infection
History
Polymerase Chain Reaction
reverse transcriptase polymerase chain reaction
Infection
history

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Rondy, M., Launay, O., Castilla, J., Costanzo, S., Puig-Barberà, J., Gefenaite, G., ... InNHOVE/I-MOVE+working group (2017). Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza. Vaccine, 35(34), 4298-4306. https://doi.org/10.1016/j.vaccine.2017.06.088

Repeated seasonal influenza vaccination among elderly in Europe : Effects on laboratory confirmed hospitalised influenza. / Rondy, Marc; Launay, Odile; Castilla, Jesus; Costanzo, Simona; Puig-Barberà, Joan; Gefenaite, Giedre; Larrauri, Amparo; Rizzo, Caterina; Pitigoi, Daniela; Syrjänen, Ritva K.; Machado, Ausenda; Kurečić Filipović, Sanja; Krisztina Horváth, Judit; Paradowska-Stankiewicz, Iwona; Marbus, Sierk; Moren, Alain; InNHOVE/I-MOVE+working group .

In: Vaccine, Vol. 35, No. 34, 03.08.2017, p. 4298-4306.

Research output: Contribution to journalArticle

Rondy, M, Launay, O, Castilla, J, Costanzo, S, Puig-Barberà, J, Gefenaite, G, Larrauri, A, Rizzo, C, Pitigoi, D, Syrjänen, RK, Machado, A, Kurečić Filipović, S, Krisztina Horváth, J, Paradowska-Stankiewicz, I, Marbus, S, Moren, A & InNHOVE/I-MOVE+working group 2017, 'Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza', Vaccine, vol. 35, no. 34, pp. 4298-4306. https://doi.org/10.1016/j.vaccine.2017.06.088
Rondy, Marc ; Launay, Odile ; Castilla, Jesus ; Costanzo, Simona ; Puig-Barberà, Joan ; Gefenaite, Giedre ; Larrauri, Amparo ; Rizzo, Caterina ; Pitigoi, Daniela ; Syrjänen, Ritva K. ; Machado, Ausenda ; Kurečić Filipović, Sanja ; Krisztina Horváth, Judit ; Paradowska-Stankiewicz, Iwona ; Marbus, Sierk ; Moren, Alain ; InNHOVE/I-MOVE+working group . / Repeated seasonal influenza vaccination among elderly in Europe : Effects on laboratory confirmed hospitalised influenza. In: Vaccine. 2017 ; Vol. 35, No. 34. pp. 4298-4306.
@article{5bc9429b8751479db39a7f7b3d87d66c,
title = "Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza",
abstract = "In Europe, annual influenza vaccination is recommended to elderly. From 2011 to 2014 and in 2015–16, we conducted a multicentre test negative case control study in hospitals of 11 European countries to measure influenza vaccine effectiveness (IVE) against laboratory confirmed hospitalised influenza among people aged ≥65 years. We pooled four seasons data to measure IVE by past exposures to influenza vaccination. We swabbed patients admitted for clinical conditions related to influenza with onset of severe acute respiratory infection ≤7 days before admission. Cases were patients RT-PCR positive for influenza virus and controls those negative for any influenza virus. We documented seasonal vaccination status for the current season and the two previous seasons. We recruited 5295 patients over the four seasons, including 465A(H1N1)pdm09, 642A(H3N2), 278 B case-patients and 3910 controls. Among patients unvaccinated in both previous two seasons, current seasonal IVE (pooled across seasons) was 30{\%} (95{\%}CI: −35 to 64), 8{\%} (95{\%}CI: −94 to 56) and 33{\%} (95{\%}CI: −43 to 68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively. Among patients vaccinated in both previous seasons, current seasonal IVE (pooled across seasons) was −1{\%} (95{\%}CI: −80 to 43), 37{\%} (95{\%}CI: 7–57) and 43{\%} (95{\%}CI: 1–68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively. Our results suggest that, regardless of patients’ recent vaccination history, current seasonal vaccine conferred some protection to vaccinated patients against hospitalisation with influenza A(H3N2) and B. Vaccination of patients already vaccinated in both the past two seasons did not seem to be effective against A(H1N1)pdm09. To better understand the effect of repeated vaccination, engaging in large cohort studies documenting exposures to vaccine and natural infection is needed.",
author = "Marc Rondy and Odile Launay and Jesus Castilla and Simona Costanzo and Joan Puig-Barber{\`a} and Giedre Gefenaite and Amparo Larrauri and Caterina Rizzo and Daniela Pitigoi and Syrj{\"a}nen, {Ritva K.} and Ausenda Machado and {Kurečić Filipović}, Sanja and {Krisztina Horv{\'a}th}, Judit and Iwona Paradowska-Stankiewicz and Sierk Marbus and Alain Moren and {InNHOVE/I-MOVE+working group}",
year = "2017",
month = "8",
day = "3",
doi = "10.1016/j.vaccine.2017.06.088",
language = "English",
volume = "35",
pages = "4298--4306",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "34",

}

TY - JOUR

T1 - Repeated seasonal influenza vaccination among elderly in Europe

T2 - Effects on laboratory confirmed hospitalised influenza

AU - Rondy, Marc

AU - Launay, Odile

AU - Castilla, Jesus

AU - Costanzo, Simona

AU - Puig-Barberà, Joan

AU - Gefenaite, Giedre

AU - Larrauri, Amparo

AU - Rizzo, Caterina

AU - Pitigoi, Daniela

AU - Syrjänen, Ritva K.

AU - Machado, Ausenda

AU - Kurečić Filipović, Sanja

AU - Krisztina Horváth, Judit

AU - Paradowska-Stankiewicz, Iwona

AU - Marbus, Sierk

AU - Moren, Alain

AU - InNHOVE/I-MOVE+working group

PY - 2017/8/3

Y1 - 2017/8/3

N2 - In Europe, annual influenza vaccination is recommended to elderly. From 2011 to 2014 and in 2015–16, we conducted a multicentre test negative case control study in hospitals of 11 European countries to measure influenza vaccine effectiveness (IVE) against laboratory confirmed hospitalised influenza among people aged ≥65 years. We pooled four seasons data to measure IVE by past exposures to influenza vaccination. We swabbed patients admitted for clinical conditions related to influenza with onset of severe acute respiratory infection ≤7 days before admission. Cases were patients RT-PCR positive for influenza virus and controls those negative for any influenza virus. We documented seasonal vaccination status for the current season and the two previous seasons. We recruited 5295 patients over the four seasons, including 465A(H1N1)pdm09, 642A(H3N2), 278 B case-patients and 3910 controls. Among patients unvaccinated in both previous two seasons, current seasonal IVE (pooled across seasons) was 30% (95%CI: −35 to 64), 8% (95%CI: −94 to 56) and 33% (95%CI: −43 to 68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively. Among patients vaccinated in both previous seasons, current seasonal IVE (pooled across seasons) was −1% (95%CI: −80 to 43), 37% (95%CI: 7–57) and 43% (95%CI: 1–68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively. Our results suggest that, regardless of patients’ recent vaccination history, current seasonal vaccine conferred some protection to vaccinated patients against hospitalisation with influenza A(H3N2) and B. Vaccination of patients already vaccinated in both the past two seasons did not seem to be effective against A(H1N1)pdm09. To better understand the effect of repeated vaccination, engaging in large cohort studies documenting exposures to vaccine and natural infection is needed.

AB - In Europe, annual influenza vaccination is recommended to elderly. From 2011 to 2014 and in 2015–16, we conducted a multicentre test negative case control study in hospitals of 11 European countries to measure influenza vaccine effectiveness (IVE) against laboratory confirmed hospitalised influenza among people aged ≥65 years. We pooled four seasons data to measure IVE by past exposures to influenza vaccination. We swabbed patients admitted for clinical conditions related to influenza with onset of severe acute respiratory infection ≤7 days before admission. Cases were patients RT-PCR positive for influenza virus and controls those negative for any influenza virus. We documented seasonal vaccination status for the current season and the two previous seasons. We recruited 5295 patients over the four seasons, including 465A(H1N1)pdm09, 642A(H3N2), 278 B case-patients and 3910 controls. Among patients unvaccinated in both previous two seasons, current seasonal IVE (pooled across seasons) was 30% (95%CI: −35 to 64), 8% (95%CI: −94 to 56) and 33% (95%CI: −43 to 68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively. Among patients vaccinated in both previous seasons, current seasonal IVE (pooled across seasons) was −1% (95%CI: −80 to 43), 37% (95%CI: 7–57) and 43% (95%CI: 1–68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively. Our results suggest that, regardless of patients’ recent vaccination history, current seasonal vaccine conferred some protection to vaccinated patients against hospitalisation with influenza A(H3N2) and B. Vaccination of patients already vaccinated in both the past two seasons did not seem to be effective against A(H1N1)pdm09. To better understand the effect of repeated vaccination, engaging in large cohort studies documenting exposures to vaccine and natural infection is needed.

UR - http://www.scopus.com/inward/record.url?scp=85022092145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022092145&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2017.06.088

DO - 10.1016/j.vaccine.2017.06.088

M3 - Article

AN - SCOPUS:85022092145

VL - 35

SP - 4298

EP - 4306

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 34

ER -